- Home
- ELDN vs KOD Comparison
ELDN vs KOD Comparison
Compare ELDN & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- KOD
- Stock Information
- Founded
- ELDN 2004
- KOD 2009
- Country
- ELDN United States
- KOD United States
- Employees
- ELDN N/A
- KOD N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELDN Health Care
- KOD Health Care
- Exchange
- ELDN Nasdaq
- KOD Nasdaq
- Market Cap
- ELDN 202.4M
- KOD 198.4M
- IPO Year
- ELDN N/A
- KOD 2018
- Fundamental
- Price
- ELDN $2.59
- KOD $9.99
- Analyst Decision
- ELDN Strong Buy
- KOD Hold
- Analyst Count
- ELDN 2
- KOD 4
- Target Price
- ELDN $12.50
- KOD $11.75
- AVG Volume (30 Days)
- ELDN 683.9K
- KOD 673.8K
- Earning Date
- ELDN 08-14-2025
- KOD 08-13-2025
- Dividend Yield
- ELDN N/A
- KOD N/A
- EPS Growth
- ELDN N/A
- KOD N/A
- EPS
- ELDN 0.21
- KOD N/A
- Revenue
- ELDN N/A
- KOD N/A
- Revenue This Year
- ELDN N/A
- KOD N/A
- Revenue Next Year
- ELDN N/A
- KOD N/A
- P/E Ratio
- ELDN $12.78
- KOD N/A
- Revenue Growth
- ELDN N/A
- KOD N/A
- 52 Week Low
- ELDN $2.38
- KOD $1.92
- 52 Week High
- ELDN $5.54
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ELDN 41.11
- KOD 60.34
- Support Level
- ELDN $2.54
- KOD $8.29
- Resistance Level
- ELDN $2.84
- KOD $9.23
- Average True Range (ATR)
- ELDN 0.13
- KOD 0.90
- MACD
- ELDN 0.03
- KOD -0.11
- Stochastic Oscillator
- ELDN 22.73
- KOD 64.46
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.